NEWS
Advancements in Patient-Centered Care
Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
LEGISLATIVE VICTORIES FOR ONCOLOGY PATIENTS IN ALABAMA & OKLAHOMA
May 17, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
TAKING A STAND FOR TEXANS WITH CANCER
May 12, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
Patient Access Network (PAN) Foundation | Patient Assistance Funds
May 6, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
April 29, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker
April 26, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
NCODA Welcomes New Executive Council Member – Lucius Daniel, PharmD
April 26, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
April 12, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance
March 23, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
March 8, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
Now Approved: PEPAXTO® (melphalan flufenamide); Oncopeptides, Inc.
March 5, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
ANY WILLING PROVIDER (AWP) – STILL A MAJOR ISSUE IN ONCOLOGY
February 23, 2021
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
![](https://www.ncoda.org/wp-content/uploads/2022/09/ncoda_horizontal_full_color1-min.png)
FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
February 23, 2021
RESOURCES
Cost Avoidance Waste Tracker
PQI in Action
OCE Sheets
IVE Sheets
Treatment Support Kits
PQI Podcast
Members
Member Resources
OPTA
Committees
Member Login
Events
Webinars
Spring Forum
Oncology Institute
PSO Annual Meeting
Fall Summit
315-655-4640
P.O. Box 468
Cazenovia, NY 13035
NURSE RESOURCES
Through collaboration between oncology nurses throughout North America, these resources are available to all NCODA members.